We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 93.08 | 92.10 | 93.20 | 0.00 | 01:00:00 |
From May 2019 to May 2024
-- French drugmaker Sanofi SA (SNY) plans to appoint Paul Hudson, a top executive with Switzerland's Novartis, to become its next chief executive, Reuters reported Thursday, citing a source familiar with the decision.
-- Current Sanofi CEO Olivier Brandicourt will leave the company to retire, the report said.
-- Hudson was chosen because of his reputation and is known as a solid manager and has an expertise in digital relating to pharmaceuticals, the report said.
Write to Patrick Thomas at patrick.thomas@wsj.com
(END) Dow Jones Newswires
June 06, 2019 18:57 ET (22:57 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
